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 Report of workshop on low dose and non-monotonic effects of endocrine disruptors.
 Need for research on low dose effects and non-monotonic dose responses to EDCs.
 No consensus on importance of non-monotonic responses to risk assessment.
 Changes needed to risk assessments to accommodate EDC effects.
 More workshops and improved communication between relevant parties.a r t i c l e i n f o
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A workshop was held in Berlin September 12–14th 2012 to assess the state of the science of the data sup-
porting low dose effects and non-monotonic dose responses (‘‘low dose hypothesis’’) for chemicals with
endocrine activity (endocrine disrupting chemicals or EDCs). This workshop consisted of lectures to pres-
ent the current state of the science of EDC action and also the risk assessment process. These lectures
were followed by breakout sessions to integrate scientists from various backgrounds to discuss in an
open and unbiased manner the data supporting the ‘‘low dose hypothesis’’. While no consensus was
reached the robust discussions were helpful to inform both basic scientists and risk assessors on all
the issues. There were a number of important ideas developed to help continue the discussion and
improve communication over the next few years.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction processes, used by regulatory agencies around the world, haveThere are continuing discussions in Europe and the United
States to identify and develop the best methods to translate scien-
tiﬁc ﬁndings to human health risk assessment. Risk assessmentbeen developed based on the principles of toxicology where it is
generally assumed that the response of an organism to a toxicant
increases with increasing level and duration of exposure (known
as a monotonic dose response). Moreover for many chemicals atitute for
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verse effect below a certain exposure level. However there is a
class of toxicants, endocrine disrupting chemicals (EDCs), for
which there is evidence that they do not obey the principles of tox-
icology. Thus there are data showing effects at doses below appar-
ent no effect levels in toxicity studies conducted according to
current standard protocols. In addition, there are data showing that
EDCs in some cases show non-monotonic dose responses (NMDRs).
In these cases extrapolation from effects observed at high doses to
human/environmental exposure levels may not be applicable. This
so-called ‘low dose hypothesis’ challenges the traditional dose–re-
sponse paradigm in toxicology and has been received with skepti-
cism and caution by some scientists including many risk
assessment practitioners. This topic is of special interest now be-
cause of the need to develop criteria for the identiﬁcation and
assessment of EDCs for application under various chemical control
regulations in the European Union.
Over the past decade there have been several meetings address-
ing the ‘‘low dose’’ paradigm and its implications for risk assess-
ment. The ﬁrst formal assessment of the effects of chemicals at
doses lower than those traditionally tested was held at the National
Institute of Environmental Health Sciences (NIEHS) in collaboration
with the US Environmental Protection Agency (EPA) in 2001 (Mel-
nick et al., 2002). This scientiﬁc peer review of the data provided a
‘‘rigorous, open, transparent, and objective evaluation of the scien-
tiﬁc evidence showing the presence or absence of low-dose effects
of endocrine disrupting agents. . .’’. The workshop veriﬁed low dose
effects for four EDCs (diethylstilbestrol, genistein, methoxyclor, and
nonylphenol) and estradiol. The workshop report noted that ‘‘the
ﬁndings of the panel indicate that the current testing paradigmused
for assessments of reproductive and developmental toxicity should
be revisited to see whether changes are needed regarding dose
selection, animal-model selection, age when animals are evaluated,
and the end points being measured following exposure to endo-
crine-active agents.’’ In the following years there were reviews fo-
cused on ‘‘low dose’’ effects of bisphenol A (BPA) (vom Saal and
Hughes, 2005; vom Saal et al., 2007) but no institutional attempts
to analyze or examine the wider low dose literature.
In 2009, the German Federal Institute for Risk Assessment (BfR)
held a workshop to establish assessment and decision criteria in
human risk assessment for substances with potential endocrine
disrupting properties focusing on active substances in plant pro-
tection products (Federal Institute for Risk Assessment (BfR),
2009). While this workshop was not focused on low dose effects,
one point of discussion was whether effects occur at doses below
those normally tested and if NMDRs exist for EDCs. Several recom-
mendations were made:
1. Robust evidence of low dose effects of endocrine disrupting
substances was considered to be important to be estab-
lished before regulatory action might be taken. This evi-
dence should include reproducibility of effects with the
same compound in different studies.
2. Funding of international projects for the validation of meth-
ods and the development of new methodology to assess low
dose effects as well as the development of a literature
search on evidence for potential low dose effects of sub-
stances with endocrine disrupting properties were
recommended.
3. The development of workshops on low dose issues was con-
sidered to be of major relevance.
Responding to BfR’s meeting conclusions, a group of scientists
developed a comprehensive review of the low dose and NMDR lit-
erature (Vandenberg et al., 2012). The authors concluded that low
dose effects and NMDRs are to be expected for chemicals withendocrine disrupting activity and that these responses may occur
frequently enough to be a concern. The review focused in part on
the evidence of associations between current human exposures
to various chemicals and speciﬁc diseases and in part on the data
showing that these observations are supported by mechanistic
in vitro and animal studies.
The Vandenberg et al. review stimulated the development of
several workshops on the topic of low dose effects and NMDR.
For instance, shortly after its publication The Pew Charitable Trusts
held a workshop cosponsored by the journal Nature and the Insti-
tute of Food Technologists (see discussion of presentation by Tom
Neltner, below). This multidisciplinary workshop included more
than 60 leading scientists from government, academia, private sec-
tor and non-proﬁt organizations from Europe and North America.
The take away messages were that the public health implications
of not being able to predict adverse health effects at doses relevant
to human exposures are signiﬁcant enough to warrant making the
issue a priority, and that there is a need to improve the interdisci-
plinary communication of endocrinologists, toxicologists and risk
assessors to better evaluate these implications.
At a European Commission conference on ‘‘Endocrine Disrup-
tors: Current challenges in science and policy’’ in June 2012 with
over 300 participants including policy makers, academics, regula-
tory risk assessors, industry and NGO groups there was a general
recognition by most attendees that the current scientiﬁc evidence
on risks of EDC to human health and the environment supported
the need for action and that the knowledge and tools exist to iden-
tify substances with endocrine disrupting properties (http://
ec.europa.eu/environment/endocrine/index_en.htm).
Shortly thereafter the European Food Safety Authority (EFSA)
held a scientiﬁc colloquium with approximately 100 risk assessors
and researchers to discuss low dose response in toxicology and risk
assessment. Although the different views from different disciplines
did not allow for a consensus some pertinent conclusions were
noted in the report, (http://www.efsa.europa.eu/de/events/event/
120614.htm):
1. An adequate and generally accepted deﬁnition of ‘‘low-dose
effects’’ and of NMDRC is needed in order to facilitate
discussions.
2. The amount of evidence needed to decide if in a particular
case a ‘‘low-dose effect’’ or an NMDRC has to be taken into
account should be deﬁned.
3. Information may be obtained from in vitro and in vivo stud-
ies to determine biological plausibility.
4. Data on toxicokinetics,MoA and toxicodynamicswill be help-
ful to understand the nature of the observations and to link
internal dose estimates to occurrence of adverse effects.
5. The criteria for adversity should be the same for all types of
effects.
6. It should be possible to derive Points of Departure (PoDs,
NOAEL/BMDL) for risk assessment in studies with an ade-
quate (extended range) number of dose levels, in particular
in the lower dose range and even if there is a NMDR.
7. Information should be obtained from well-designed studies
covering wide dose ranges with more than usual dose
groups and sufﬁcient animals per group.
8. Dose selection may be based on observations in epidemio-
logical studies or on estimates of human exposure to cover
the low exposure ranges more adequately.
9. It was noted that although the established principles of tox-
icological risk assessment would still be applicable, adapta-
tion of these techniques might be needed.
10. It was generally considered that tiered approaches for haz-
ard assessment guided by exposure estimates might not be
adequate for substances for which an NMDRC is suspected.
C. Beausoleil et al. / Chemosphere 93 (2013) 847–856 849Overall, participants considered that the existing risk assess-
ment paradigm is applicable to assess risks that could be associ-
ated with low dose/non-monotonic responses. Some participants
stated that NMDRC should not be disregarded in risk assessment,
whereas others underscored the necessity to understand the mode
of action before drawing conclusions for risk assessment.
Thus, implementation of ‘‘low-dose effects’’ and NMDRCs in risk
assessment strategies presents a scientiﬁc challenge and develop-
ment of intelligent testing strategies to deal with these phenomena
is necessary.
It was clear that different views on the signiﬁcance of ‘‘low-dose
effects’’ and NMDRCs might circulate in different scientiﬁc disci-
plines. Assuming that low-dose effects and NMDRCs are to be ac-
cepted as a ‘‘fact-of-life’’, it should be decided whether these are
applicable for speciﬁc MoA, or whether they are universal princi-
ples applicable to any MoA.
From the discussions, it became clear that there is a need for an
in-depth analysis of available studies in which these phenomena
have been reported. It was recommended that as a follow-up, EFSA
should consider to set up an ad hoc multidisciplinary working
group to examine the scientiﬁc evidence for ‘‘low-dose effects’’
and NMDRCs, and for which MoAs they are applicable.’’ See discus-
sion of presentation by Iona Pratt, below and the EFSA report
(EFSA, 2012).2. Workshop overview
In order to highlight the recent data on low dose effects and
NMDRs for EDCs and to examine data gaps and needs and possible
implications of these data for risk assessment a workshop was
developed by a planning committee composed of basic scientists,
toxicologists, endocrinologists and representatives of regulatory
agencies including risk assessors.
The overall goal of the ‘‘Low Dose Effects and Non-monotonic
Dose Responses for Endocrine Active Chemicals: Science to Prac-
tice’’ Workshop was to determine whether the current data on
low dose effects and NMDR for endocrine active compounds (EACs)
are sufﬁcient to re-examine the ways in which chemicals are tested
for endocrine disrupting properties and how risk to human health
should be assessed. This workshop was designed to build off the
previous workshops using the Vandenberg et al. review article as
a key starting point.
The speciﬁc objectives of the workshop are shown in Table 1.
Since the discussion topics were considered to be controversial,
the workshop was speciﬁcally designed to provide an atmosphere
of open, robust and transparent discussion. Key aspects of the de-
sign and approach included:
 Open and free registration.
 Planning committee** with representatives from both basic sci-
encenacademic research backgrounds, and regulatory risk
assessment agencies (**Members listed at end of article).
 Consensus not required nor expected.
 Neutral expert facilitators led the discussions in the plenary and
breakout sessions to support balanced and respectful
discussions.
 Participants were given the option to ask questions anony-
mously, and reports from break-out groups contained no indi-
vidual attribution.
 Polling devices used throughout the workshop provided real-
time information as to participant opinions to speciﬁc ques-
tions. The poll answers were anonymous; each participant
received a random device with a serial number that he/she kept
for 3 d and the responses were tracked by serial number only.
This method enabled organizer to:– Reﬁne discussion group sizes and topics.
– Get feedback from all participants on their analysis.
– Report participant feedback to speciﬁc questions presented
with demographic information.
 There were two rounds of breakout sessions:
– The ﬁrst one was a brainstorming session to cultivate and
share opinions and perspectives among participants with
like-minded ideas, self-selected by polling.
– In the second break out, groups were reconstituted to bring
together people with a range of perspectives to discuss spe-
ciﬁc aspects and to reﬁne their ideas, capture the range of
views on key issues, identify areas of general agreement
and develop a plan for next steps.
Another unique characteristic of the workshop was the devel-
opment of a ‘‘general hypothesis’’ by the planning committee. This
concept, relying on internationally acknowledged key terms, was
used to provide the framework for discussion. It also allowed poll-
ing of participants on their stance on speciﬁc issues. The general
hypothesis and deﬁnitions are noted in the supplementary
information.
The complete workshop program including PDFs of the presen-
tations can be found at
http://ihcp.jrc.ec.europa.eu/our_activities/food-cons-prod/
endocrine_disrupters/presentations-workshop-low-dose-effects-
endocrine-active-chemicals.
In addition to lectures, breakout sessions, and reports from
prior meetings, there were updates from:
 U.S. Environmental Protection Agency: Mark Miller introduced
EPA’s Non-monotonic Dose Response Curve (NMDRC) Work
plan with the goal of publishing the agency Position Paper after
addressing the following questions:
– Do non-monotonic dose response curves (NMDRC) exist for
chemicals and if so under what conditions do they occur?
– Do NMDRCs capture adverse effects that are not captured
using our current chemical testing strategies?
– Do NMDRCs provide key information that would alter EPA’s
current weight of evidence conclusions and risk assessment
determinations, either qualitatively or quantitatively?
 Endocrine Society: Ana Soto summarized the society’s Statement
of Principles on Endocrine-disrupting Chemicals and Public
Health Protection published in Endocrinology in June 2012
(Zoeller et al., 2012). She emphasized the society’s proposal of
using principles of endocrinology to identify and manage EDC
risk and the potential irreversible damage caused by exposure
to low doses of EDCs during developmental stages.
 ANSES France: Claire Beausoleil presented a work ongoing at
ANSES on NMDRCs in the ﬁeld of endocrine disruption. The
plausibility of non-monotonicity was assessed using two crite-
ria: statistical plausibility and biological plausibility. These cri-
teria of analysis were developed, based on those initially
developed for hormesis, and the biological mechanisms that
may be involved were discussed. Fifty-one experimental studies
were selected, involving several substances and various effects.
Criteria of analysis were applied on 148 NMDRCs. About 55% of
them were considered to have a ‘‘moderate’’ to a ‘‘high’’ level of
statistical plausibility. Some biases, like cytotoxicity, were dis-
cussed. It was highlighted that before considering non-monoto-
nicity in risk assessment, the quality of the NMDRCs has to be
assessed. A methodology as well as a decision tree was pro-
posed for testing their plausibility.
 National Toxicology Program: Kembra Howdeshell presented a
summary of the BPA consortium (called CLARITY-BPA). This is
a project supported by NIEHS extramural funding to academic
scientists, the National Toxicology Program at NIEHS and the
Table 1
Workshop objectives.
1. To present and discuss the state of the science for low dose effects and non-monotonic dose response curves for chemicals with endocrine activity
2. To deﬁne research needs required to move closer to scientiﬁc agreement on low dose effects and non-monotonic dose responses for endocrine active substances
3. To deﬁne how research programs, especially those funded by public agencies, could support studies that would produce data most useful for a science-based risk
assessment
4. To start a discussion on the implications of low dose effects and non-monotonic dose response curves to risk assessment
5. To develop a plan to continue discussions between basic researchers and risk assessment scientists beyond the current workshop
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additional doses (total of six plus two positive controls) and dis-
ease focused endpoints assessed blindly by academic research-
ers who had previously shown these endpoints in their
publications (Birnbaum et al., 2012).
3. Setting the stage
Fred vom Saal and Scott Belcher focused on the principles of
endocrinology and pharmacology, respectively. The principles of
endocrinology establish that hormones:
 Coordinate the development and function of tissues in a highly
integrated manner.
 Act via receptors, which are speciﬁc, sensitive, and amplify the
response.
 Bind to the receptors which are most sensitive to the hormones
at the low end of the dose response curve.
 Have afﬁnity for receptors which is distinct from overall in vivo
potency.
 Produce effects at very low concentrations, in the ppt–ppb
range.
 Bind to different receptors as dose increases, resulting in
responses not seen at low doses.
 Often result in non-monotonic dose responses due to multiple
mechanisms.
 Produce effects that are life stage dependent, with permanent
effects occurring following activity during development.
Vom Saal also noted that fetuses lack systemic feedback mech-
anisms that are present and important in adults. He proposed that
the principles of endocrinology should be applied when testing
chemicals for endocrine disrupting activity because many EDCs
act via receptors, suggesting that EDCs may also show low dose
and tissue speciﬁc effects, possibly irreversible during develop-
ment and should be expected to show NMDR.
Scott Belcher noted that examples of NMDR are well accepted in
pharmacology for both therapeutic and toxic actions of natural and
synthetic compounds including essential nutrients. However, in
toxicology, similar NMDR are sometimes considered ‘‘spurious’’
or not ‘‘dose responsive’’ or not ‘‘toxicologically relevant’’. He also
discussed the theory of receptor occupancy and effects; the com-
plexity of receptor subtypes; the effects of co-regulators on hor-
mone response elements; how different ligands could result in
different effects via the same receptor; and how positive and neg-
ative feedback loops may be responsible for NMDR.
Theo Vermeire gave an overview of the principles of risk assess-
ment. He noted that there is a speciﬁc framework for risk assess-
ment which focuses on hazard and exposure assessments while
paying attention to uncertainty. Data quality is an important part
of the evaluation process and consists of validity of the methods,
reliability of test results, consistency and reproducibility of the ef-
fects and relevance. Example criteria were discussed brieﬂy. The
relevance of observations for humans should be evaluated based
on the postulated mode of action. Regarding adversity of effects
he noted that risk assessors discriminate between adversity and
adaptive or transient effects. When considering the mode of actionof a substance there is a need to establish a causal and possibly
dose/concentration relation between in vitro/in vivo mechanistic
biomarkers and the adverse apical endpoint. Dose response data
from all reliable and relevant studies are used to decide on mode
of action and the leading health effects. He acknowledged that
the current risk assessment paradigm is based on the assumption
of monotonicity. Finally, uncertainty and variability regarding
duration of exposure, intraspecies sensitivity and interspecies tox-
icodynamic and toxicokinetic differences are assessed.4. Main topics arising from breakout sessions
Although a variety of issues and ideas were discussed, they can
be grouped into six topics: general hypothesis, low dose, NMDRs,
experimental design, risk assessment and weight of evidence,
and steps to move forward. Instead of presenting a session by ses-
sion report of the workshop this overview will focus on the six
important topics that were discussed and integrate the data on
these topics together. Below we summarize:
 The presentations associated with each of the issues.
 Polling results.
The summary of the breakout discussions reported out to the
entire group were formatted into tables as noted below.4.1. General hypothesis
The general hypothesis stated:
In the context of risk/safety assessments for food, consumer
products, and environmental exposures:
(1) Endocrine disruptors may cause adverse effects at levels rel-
evant to human or environmental exposures.
(2) These effects may, in some cases, be represented by non-
monotonic dose response curves.
(3) These curves are common enough to warrant formal consid-
eration in risk/safety assessments.
On day 1, the participants were askedwhether they could accept
the general hypothesis and the three deﬁnitions (described in Sup-
plemental materials) as a starting point for discussions in the work-
shop. Almost 50% responded that they agreed with them and
support their use; 42% said they do not necessarily agree with some
or all of the hypothesis but agreed to support its use as a starting
point for discussion, and about 9% did not agreewith the hypothesis
and would not support it as a starting point for discussion.
On the last day, participants were polled again (Fig. 1). Because
of concerns that the hypothesis was ambiguous, the multiple
choice answers were modiﬁed. Polls showed that:
 33% Agreed with the hypothesis.
 47% Could agree if terms were deﬁned or with some minor
adjustments to the language.
 12% Could possibly agree but not without major changes.
 8% Did not agree.
Fig. 1. Polling results at conclusion of meeting. Question: Do you agree with the
general hypothesis? In the context of risk/safety assessments for food, consumer
products, and environmental exposures: (1) endocrine disruptors may cause
adverse effects at levels relevant to human or environmental exposures; (2) these
effects may, in some cases, be represented by non-monotonic dose response curves;
and (3) these curves are common enough to warrant formal consideration in risk/
safety assessments.
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4.2. Breakout sessions
There were two breakout groups on day 2 consisting of partic-
ipants that supported the general hypothesis and brainstormed
around the topics of how to reﬁne risk assessment or how to over-
haul risk assessment. Eighty-ﬁve percent of the participants partic-
ipated in these breakout groups.
The reﬁne risk assessment brainstorming breakout included
participants who based on polling results accepted or accepted
for the purposes of the discussion that adverse effects at low doses
may be common enough to warrant consideration but think that
the risk assessment paradigm only needs to be reﬁned to accom-
modate the ﬁndings. They were charged with identifying speciﬁc
changes to current risk assessment methods with a focus on iden-
tifying low dose effects and NMDR.
The overhaul risk assessment brainstormingbreakout included
participants who based on polling results accepted or accepted
for the purposes of discussion that adverse effects at low doses
may be common enough to warrant consideration but think that
the risk assessment paradigm needs to be substantially changed
to respond to NMDRs at low doses. They were charged with
explaining why the current risk assessment methodology must
be overhauled rather than reﬁned and identifying speciﬁc changes
needed to each of the four steps in a risk assessment.
These breakout sessions had a robust and open discussion of the
issues. Since these were brainstorming sessions the results are not
presented here but ideas generated were used by the participants
during the day three breakout sessions.
The smaller percentage that did not support the hypothesis as a
starting point for discussion (15 participants) were assigned to a
third breakout group and charged to:
 Identify one or more speciﬁc changes to the general hypothesis
and the three deﬁnitions and explain the rationale for the
changes. Describe research studies that would effectively test the new
hypothesis based on the changes proposed.
These 15 participants concluded that the general hypothesis
was comprised of three different hypotheses and that each was
ﬂawed, also indicating that the ﬁrst item lacked precise language,
the second stated nothing new, and the third used the term ‘‘com-
mon enough’’ which was too general.
This group did not develop an alternative hypothesis. Instead
they agreed that ‘‘reﬁnement of current toxicological methods
should adequately account for endocrine disruption.’’ They called
for ‘‘evolution not revolution’’ and said that research studies
should ‘‘target efforts on evaluating current testing methodology
and making necessary reﬁnements.’’
On day 3 ﬁve breakout groups were organized, one on data
gaps, two on experimental design issues and two on risk assess-
ment methodology. Participants were assigned to the breakout
groups based on polling results and the goal of ensuring adiverse
mix of perspectives and keeping the number of participants equal
in each session. The questions asked in the breakout sessions can
be found in the Supplemental material. The responses to questions
related to these breakouts can be found in Tables 2–7.
4.3. Low dose effects
Tyrone Hayes introduced low dose effects for EACs (the terms
EACs and EDCs were not formally differentially deﬁned and were
used interchangeably throughout the workshop), deﬁned as either
effects occurring at doses lower than those typically used in stan-
dard testing protocols, or in the range of human exposure. He re-
ported that, in addition to the four EDCs described in the 2002
NTP report, low dose effects have been shown for another 24 EDCs
(Vandenberg et al., 2012). He stated that this low number may be
due to the fact that the majority of EACs have not been tested at
‘‘low doses’’. He detailed weight of evidence analysis for atrazine
and BPA developed using principles of endocrinology. Evidence
for low dose effects was given higher weight when there were mul-
tiple studies, that were performed in multiple labs; additional con-
siderations included whether the experimental model was
responsive to low doses of hormones, the system was free from
contamination and positive and negative controls were used. He
concluded that low dose effects should be expected for EDCs be-
cause they follow the same ‘‘rules’’ as hormones.
The low dose issue was discussed in several breakout sessions
on day three. Table 2 shows the results of discussions in breakouts
related to experimental design issues related to low dose effects.
Data gaps and needs in the area of low dose effects and NMDR
identiﬁed in breakout sessions are noted in Tables 3–5 and possible
steps over the next 5 years to address low dose effects and NMDR
are noted in Table 6.
Fig. 2A shows a summary of the polling results related to low
dose effects. An additional question was also asked:
Question: the deﬁnition of low dose should be:
 Human exposure range and/or environmental levels: 41%.
 Any dose at or below the NOAEL of the most sensitive species
tested: 18%.
 NOAEL divided by an uncertainty factor (which could be ﬂexible
or ﬁxed): 7%.
 No formal deﬁnition is needed, just state what you mean: 22%.
 Other: 12%.
4.4. Non-monotonic dose response issues
Laura Vandenberg described the state of the science for NMDR
for EDCs. She started by noting that
Table 4
Experimental design issues related to NMDR.a
 NMDR must be reproducible and consistent across laboratories
– Consider background contamination (feed, reagents, tissue culture
materials)
– Consider variability due to animal stress, circadian rhythms
– Reproduce effects within labs before publication
– Evaluation criteria for assessment of dose responses for non-monoto-
nicity should be included in manuscripts
 Encourage funding and publication of two laboratories with same ques-
tion/approach/dose range
 Authors should evaluate dose responses for NMDR using statistical anal-
ysis and report results as part of discussion in manuscripts
a Points taken from breakout group reports, some wording changes for clarity and
to avoid overlap.
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changes slope from one direction to another and therefore
can occur in any part of the dose response curve, not only
at low doses.
(2) Natural hormones show NMDR but not necessarily for every
endpoint and for all tissues. She showed examples of NMDR
from guideline studies and epidemiology studies, while pro-
viding more than 30 examples of chemicals showing NMDR
in vitro and in vivo.
Vandenberg also discussed whether the endpoints showing
NMDR are adverse; and indicated that, while some of the end-
points noted would be considered adverse in guideline studies,
most would be considered adverse by endocrinologists. She high-
lighted that not all regulatory agencies have a deﬁnition of adverse
effect; therefore the determination of adversity often relies on ex-
pert judgment. She ended by acknowledging the need for NMDR
reproducibility and underscoring that the occurrence of NMDR
challenges the idea that high doses can predict the effects of chem-
icals at lower doses.
Rory Connolly discussed computational modeling of NMDR, and
started by indicating that a study with only three doses covering a
high dose range cannot answer the question of whether NMDR ex-
ists. He explained different intracellular factors leading to NMDR
such as saturation of metabolic pathways, alteration of signaling
pathways and induction of detoxiﬁcation pathways. Additionally,
NMDR can arise when xenobiotic exposure elicits at least two ef-
fects and when these effects can individually affect a common end-
point, such as simultaneously increasing the number of adducts
and their repair mechanism. He concluded that ongoing research
on toxicokinetics and exposures to EAC as well as its metabolitesTable 2
Experimental design issues related to low dose effects.a
 Use sensitive endpoints in sensitive animal model
 Include developmental exposures as a sensitive time for exposures
 Consider lifetime exposure studies
 Use three or more doses
 Analyze experimental design for statistical power
 Measure internal dose of environmental chemical to aid in extrapolation
to humans
a Points taken from breakout group reports, some wording changes for clarity and
to avoid overlap.
Table 3
Data gaps and needs in area of low dose effects and NMDR.a
There is a need for:
 ‘Appropriate’ data on chemicals to judge binding afﬁnity and intrinsic
activity at a receptor compared to endogenous hormone
– At what point is the potency so high that it is of concern relative to the
effects that can occur with high afﬁnity and high intrinsic activity?
 Human exposure data for new and existing chemicals
 Environmental (wildlife) exposure data for new and existing chemicals
 To determine if low dose effects are relevant for ecotoxicity at the popu-
lation level
 Information on internal dose from in vitro and in vivo experiments in
order to be able to translate across species
 Information on reproducibility of experiments and adversity of endpoints
measured as they relate to low dose studies
 To include/address issues of variability, reproducibility and information
on chemical purity in studies assessing low dose effects and NMDR
 Determination of what ﬁts the deﬁnition of adverse effects
 To involve specialized experts from relevant ﬁelds to assess
toxicologicalﬁndings
 Information on endocrine mode of action besides estrogen, androgen and
thyroid
a Points taken from breakout group reports, some wording changes for clarity
and to avoid overlap.is needed for understanding when such dose–responses are likely
to occur under real-world exposure conditions.
Ana Soto noted that NMDRs are common in endocrinology and
described seven proposed mechanisms to explain their occurrence
as follows and showed examples of each mechanism:
 Cytotoxicity.
 Receptor down-regulation and desensitization.
 Cell and tissue speciﬁc receptors and cofactors.
 Receptor selectivity.
 Receptor competition.
 Negative feedback loops.
 Tissue interactions.
She explained that, in many cases, NMDR were due to compet-
ing pathways which change over a dose range. For example, an EDC
may interact with a speciﬁc receptor at low doses and, as the dose
increases, it activates other receptors and thus other pathways. An-
other mechanism is represented by the activation of different path-
ways by the same receptor at different doses such as in breast
tissue where BPA can cause cell proliferation over a large dose re-
sponse but at higher doses it causes apoptosis. These competing
pathways lead to NMDR. She also noted that for many NMDR the
mechanisms are unknown but that should not be a determinant
in accepting the existence of the phenomenon.
Fig. 2B and C shows a summary of the polling results related to
NMDRs.
4.5. Experimental design issues
Olwenn Martin described endocrine endpoints within OECD
test guidelines. She noted that the OECD conceptual framework
is not a testing strategy but a 5 level toolbox that consists of vali-
dated in vitro and in vivo assays. Regarding endocrine endpoints,
OECD test guidelines focus on estrogen, androgen and thyroid ef-
fects. For example, the 28 d repeated toxicity study has been up-
dated to include endocrine endpoints mostly focusing on
histopathology and organ weight. She mentioned that although
critical windows of exposure are included in multigenerational
reproductive tests and partial or full lifecycle assays they include
limited endocrine relevant endpoints. She stated that guideline
studies usually include three dose levels based on toxic effects
and available toxicokinetic data and a control with monotonicity
assumed. However, she noted that in the 2012 guidance on chronic
toxicity and carcinogenicity assays OECD states that there may be
non-linearities in the dose response, and that doses should cover
anticipated human exposure levels. She ended saying that it would
be helpful to extend this guidance to other assays within the con-
ceptual framework and to consider additional endpoints which re-
late to additional hormonal and disease pathways.
Table 5
Experimental design issues related to low dose effects and NMDR in risk assessment.a
 Add endocrine endpoints that are not formally/currently validated to standardized toxicity tests, for example, mammary glands, glucocorticoids/stress response,
diabetes/metabolic disorders, obesogens (ppar gamma pathways)
 Identify new biomarkers that can predict environmental and public health outcomes
 Stimulate investigators to report low dose data, arbitrary ﬁndings and negative data
 Practical assessment of what ﬁts the deﬁnition of adverse effects would be good/helpful
 Standard and accepted deﬁnition of ‘‘low dose’’ is needed
 Separate the issues of low dose effects from that of NMDR
 Adapt/change guideline studies: start dose selection at low doses and look for NMDR
 Participants were evenly split whether a non-threshold model for endocrine disruptors is appropriate
 Risk assessment portfolios should include toxicokinetic data and include better internal dose data
 Build informed cases: more documentation and justiﬁcation for decisions
 Better access to raw data, especially in published papers
 Establish formal routes of communication, especially between risk assessors and academics providing data. Need transparency and better documentation of the
decision making process
 Develop new test methods for step 1 (hazard identiﬁcation) of risk assessment: assays that reﬂect endocrine endpoints and critical windows
 Enhance available assays: endocrine endpoints, critical windows (extended 1 generation study may be a good ﬁrst step)
 Address data gaps in our knowledge of exposures at vulnerable periods (fetal)
 Take into account allometry in administered doses (where appropriate) to choose ‘‘low doses’’
 Integrate existing classiﬁcation system with recognized endocrine endpoints
 Establish an agreed upon deﬁnition of ‘‘low dose’’ or ask all to be precise in their language
 Develop new test methods
 Recognize that processes need to proceed in parallel, and information needs to be continually integrated
 Studies that show an effect at low dose which disappears at high dose should not be dismissed
 Continue to use a tiered approach to exclude chemicals that are unlikely to cause endocrine disruption
 Use of QSAR and in vitro multiple dose screening to have indications for further testing
 Develop or elaborate on guidance which allows evaluation of exploratory research, to make it more useful to Risk Assessment
 Use of assays developed by exploratory research in risk assessment: aid risk assessors to understand and interpret them
 Consider using test methods with consistent results even if not formally validated
a Points taken from breakout group reports, some wording changes for clarity and to avoid overlap.
Table 6
Possible steps over 5 years to address low dose effects and NMDR.a
 Develop a knowledge base of ﬁndings of in vivo and in vitro NMDR and low dose effects in a secure database as a resource. This might include raw data
 Develop minimum information requirements for publishing NMDR using a task force of academic, regulatory, and industry laboratories. Use OECD guidelines as a
starting point
 Deﬁne adverse for purposes of low dose effects and NMDR
 Prioritize and ﬁll the data gaps noted
 Integrate existing classiﬁcation system with recognized endocrine endpoints
 Establish an agreed upon deﬁnition of ‘‘low dose’’ or ask all to be precise in their language
 Develop new QSAR training sets that also work at low doses
a Points taken from breakout group reports, some wording changes for clarity and to avoid overlap.
Table 7
Steps needed to expand/improve risk assessment over the next 5 yearsa.
 Develop and publish further guidance/criteria for increasing the use of exploratory academic studies (including power calculations and sample size) in risk
assessment
 Create and publish an evolving list of relevant adverse effects that should be looked at in toxicity studies
 Find a consensus on ‘‘low dose’’ and provide guidance on how and when to add lower doses
 Include MoA and adverse outcome pathways initiative within the low dose area (WHO and OECD)
 Determine to what extent evaluation of data from current study protocols pick up NMDR
 Determine to what extent current testing protocols pick up NMDR
 Build on OECD guidelines to make better use of current data and include additional (low) doses or effects with latency
 Implement the use of power analyses and statistical methods in choice of endpoints (including continuous versus binary), as well as the number of animals needed
 Enhance existing assays for endocrine endpoints and implement new test methods into regulation
a Points taken from breakout group reports, some wording changes for clarity and to avoid overlap.
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that discussed experimental design issues related to NMDR. Addi-
tionally, Fig. 3 shows a summary of the polling results related to
experimental design.
4.6. Risk assessment and weight of evidence issues
Studies that follow speciﬁc testing guidelines from regulatory
agencies (known as guideline studies) generate a wealth of data
regarding the potential health consequences of exposure to chem-icals. The assumptions that underlie guideline studies have a priori
impact not only on experimental design but also data analysis and
interpretation.
Heather Patisaul illustrated this point describing two studies
that followed OECD guidelines. She showed that in both cases,
the statistically signiﬁcant adverse effects either followed non-lin-
ear responses or the effects that were observed only at the lower
dose were considered by the authors to be ‘‘incidental’’ or ‘‘spuri-
ous’’ and thus ‘‘unrelated to treatment.’’ They were not reported
in the study summary or considered when establishing theNOAEL.
Fig. 2. Summary of polling results related to low dose effects and NMDRs. (A)
Question: do you agree that a low dose deﬁnition would be helpful/good? (B)
Question: Do you agree that NMDRs exist at some dose range? (C) Question: Do you
agree that NMDR is a different issue than the low dose issue?
854 C. Beausoleil et al. / Chemosphere 93 (2013) 847–856Among the adverse effects were fewer live births, skeletal malfor-
mations in the offspring, and altered adrenal, thyroid and pituitary
gland weights. Data analysis itself was also impacted by the pre-
sumption that effects would be monotonic. For example in a par-
ticular developmental toxicity study, numerous endpoints were
not statistically analyzed if an effect was not observed at the high-
est dose.
Patisaul also showed that her own work indicates that perinatal
exposure to the same chemical at a dose 10-fold lower than the
NOAEL produced statistically signiﬁcant effects consistent with
those observed in the guideline studies, suggesting that the trueNOAEL is lower than what was concluded. She stated that failing
to consider that effects might be non-monotonic in guideline stud-
ies results in the discounting of data points that might be informa-
tive for NOAEL calculation.
Alexandre Feigenbaum presented risk assessment atEFSA. He
noted that EFSA takes into account all available information,
whether from public organizations or from industry, GLP or non-
GLP and targets overall scientiﬁc consistency. He used the BPA
opinion as an example and pointed out the transparency of the
opinion, reminding that criteria set for inclusion of studies in the
risk assessment are published in the opinion. He noted that in
2010 in the preparation of its opinion on BPA, the CEF Panel had
screened more than 800 scientiﬁc studies (EFSA, 2010). These stud-
ies were critically reviewed by a large panel of experts and their
relevance to public health was carefully assessed. One of the con-
clusions was that the Panel is ‘‘not aware of any clearly reproduc-
ible adverse effect expressed speciﬁcally at low BPA doses only’’;
studies claiming for low dose effects did not meet the criteria for
inclusion in the risk assessment. He also gave the example of a
GLP study provided byindustry for that opinion and for which
the Panel did not agree with the conclusions. Feigenbaum also
pointed out that the experts of EFSA are selected on the basis of
their scientiﬁc excellence and their independence. He concluded
that EFSA is neither for nor against the low-dose hypothesis, as this
is still the subject of considerable debate. EFSA is open to any new
scientiﬁc information and is directly involved in the scientiﬁc
debate.
As part of risk assessment issues, Jim Bridges discussed the im-
pact of low dose and NMDR on future risk assessments. He indi-
cated that the pros of the current risk assessment procedures are
that they are familiar to all stakeholders, resource implications
are known, and they have a good record of protection of human
health. On the con side, they have a high demand on resources,
provide limited information on dose response relationships and
have provided a very modest contribution to advancing
scientiﬁcunderstanding.
In the current climate there are several reasons for reviewing
current risk assessment procedures, according to Bridges. These
include:
 Demands to reduce or abolish the use of animals for toxicity
testing.
 Recognized deﬁciencies in current approaches.
 The large number of untested chemicals and chemical products.
 The need to better assess effects of exposures to combinations
of chemicals.
 Advances in science and challenges posed by more complex
products such as nanotechnologies.
Bridges said that all stakeholders have an interest in modifying
current risk assessment. He showed a list of possible priorities
which included characterizing the range of human exposures,
determining critical windows for exposure relevant to man, identi-
fying vulnerable groups, understanding the impact of exposure to
multiple stressors and examining effects over a much greater dose
range. He noted that future risk assessments can be anticipated to
have better exposure measurements, more reliance on in vitro and
in silico methods, increased use of ‘‘omics’’ endpoints enabling ear-
lier detection and improved sensitivity, and a progressive change
to a mode-of-action basis for evaluating hazardous substances.
With regard to dose response he asked whether high dose effects
are relevant to exposures at lower doses; is the methodology used
to set NOAELs sufﬁciently rigorous; and are we missing effects
oftoxicological concern by not assessing low dose effects and
NMDR? He ended his presentation with a challenge: More than at
any other time risk assessment is at a crossroads one path leads to
Fig. 3. Summary of polling results related to experimental design. (A) Question: Do
you agree that a practical assessment of what ﬁts the deﬁnition of adverse effects
would be helpful/good? (B) Question: I could support the concept of adding ED
endpoints that are not formally/currently validated to standardized tests. (C)
Question: I would support the development of a list of desirable information to be
included in a peer reviewed publication so it may be useful for risk assessment.
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ture. Let’s hope we have the wisdom to choose correctly.
Fig. 4 shows a summary of the polling results which focused on
risk assessment and weight of evidence. An additional question
was also asked:Question: what is the best way of incorporating academic data
into the risk assessment process?
 63%: Develop new criteria speciﬁcally for this area research to
evaluate quality.
 28%: Use the same criteria currently used to evaluating guide-
line studies to evaluate the quality of academic studies.
 8%: The system is ﬁne the way it is.
 1%: Academic data should not be used in risk assessment.
5. Steps to move forward
The goal of the workshop was to openly discuss the hypothesis
proposed and to, based on the discussion, either accept the hypoth-
esis as is or determine what further research would be needed to
accept the hypothesis and in either case determine how acceptance
of the hypothesis would impact risk assessment. The one topic
where there was consensus is that more is needed to be done in
the area of understanding the importance and impact of low dose
effects and non-monotonic dose responses to EDCs and changes
needed to risk assessments to accommodate these effects: includ-
ing more workshops, more literature reviews and improved com-
munication between relevant parties. Breakout groups were
asked to propose ideas to move the discussion forward over the
next 5 years. Table 3 shows data gaps noted, Table 6 shows some
of the ideas discussed related to addressing low dose effects and
NMDR and Table 7 shows ideas presented relevant to expanding
or improving risk assessment.
Many of the breakout group recommendations would be facili-
tated by and may even require more formal routes of communica-
tion, especially between risk assessors and academics providing
data. A series of workshops and/or task forces of academic, regula-
tory and industry scientists to develop such guidance for publica-
tion was suggested as one possible means of moving forward the
‘‘low dose’’ hypothesis as developed at this workshop. These work-
shops would focus on the following:
 Development of guidance documents useful to both researchers
and risk assessors.
 In depth analysis to determine to what extent current study
protocols pick up NMDR and to what extent evaluation of study
protocols may overlook NMDR because of the default assump-
tion of monotonicity.
 There is a need for some guidance on minimum information
requirements for reporting non-guideline studies by research-
ers so the data would be more useful for risk assessors, as well
as guidance on how risk assessors could use these studies in
their assessments. This might be best accomplished by a work-
ing group that would develop guidance for publication.
 There was also a call from the research community for transpar-
ency and better documentation and more justiﬁcation of the
decision making process in risk assessment, this could be facil-
itated by the availability of raw data not only from research
studies but also regulatory guideline studies.
 A workshop to deﬁne additional endpoints and how to facilitate
their incorporation into guideline studies is needed to improve
the sensitivity of current guideline studies to identify endocrine
disrupting substances as done for the recently enhanced
extended one generation reproduction study. Consideration of
additional biomarkers related to human diseases of increasing
incidence, such as diabetes and breast cancer and to cover more
aspects of the endocrine system beyond estrogen, androgen and
thyroid hormone pathways was also proposed, for example,
effects on mammary glands, glucocorticoids (in relation to
stress responses), and PPAR c pathways (in relation to fatty acid
metabolism/obesity and metabolic disorders).
Fig. 4. Summary of polling results related to risk assessment and weight of
evidence. (A) Question: Principles and procedures need to be developed to promote
a more systematic use of all available data in the risk assessment process (including
non-guideline, epidemiological and biomonitoring data, etc.). (B) Question: Do you
agree to provide your raw data on request by regulators/risk assessors?
856 C. Beausoleil et al. / Chemosphere 93 (2013) 847–856 A workshop to develop a consensus on the deﬁnition of low
dose and a consensus on the signiﬁcance of the ‘low dose’ issue
followed by guidance on how and when to include ‘low doses’
in the design of toxicology studies, considering the need for
not only adding more doses to testing protocols but to start
dose selection at ‘‘low doses’’ rather than from high doses
downward.
 A knowledge base of ﬁndings in vivo and in vitro showing NMDR
and low dose effects in a secure database as a resource, which
may include raw data, was also proposed.
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